Specification:
CD19 is a transmembrane glycoprotein that contains two extracellular immunoglobulin-like domains. CD19 is present in both benign and malignant B-cells and is considered to be the reliable surface marker of this lineage over a wide range of maturational stages. In normal lymphoid tissue, CD19 is observed in germinal centers, in mantle zone cells and in scattered cells of the inter-follicular areas. Anto-CD19 exhibits an overall immunoreactivity pattern similar to those of the antibodies against CD20 and CD22. However in contrast to CD20, expression of CD19 is continuous throughout B-Cell development and trough terminal differentiation of B-cells into plasma cells. Anti-CD19 positivity is seen in the vast majority of B-cells neoplasms commonly at a lower intensity than normal B-cell counterparts. Plasma cell neoplasm are nearly always negative, as are t-cells neoplasms.
Presentation:
Bioreactor Concentrate with 0.05% BSA and 0.05% Azide
Reviews
There are no reviews yet.